261 related articles for article (PubMed ID: 1737346)
1. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
2. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
4. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects.
Rinehart JJ; Young D; Laforge J; Colburn D; Neidhart J
J Biol Response Mod; 1987 Jun; 6(3):302-12. PubMed ID: 3110379
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
7. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
8. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
Kirkwood JM; Ernstoff MS; Trautman T; Hebert G; Nishida Y; Davis CA; Balzer J; Reich S; Schindler J; Rudnick SA
J Clin Oncol; 1990 Jun; 8(6):1070-82. PubMed ID: 2112184
[TBL] [Abstract][Full Text] [Related]
9. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
10. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract][Full Text] [Related]
11. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
[TBL] [Abstract][Full Text] [Related]
12. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer.
Aulitzky WE; Aulitzky W; Gastl G; Lanske B; Reitter J; Frick J; Tilg H; Berger M; Herold M; Huber C
J Interferon Res; 1989 Aug; 9(4):425-33. PubMed ID: 2502583
[TBL] [Abstract][Full Text] [Related]
16. [Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma].
Arima K; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J; Saitoh K; Yamazaki Y; Mori O; Oomoto Y; Nakagawa M
Hinyokika Kiyo; 1994 Jun; 40(6):469-74. PubMed ID: 8073952
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
19. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
20. [Immunological assessment after radical nephrectomy for renal cell carcinomas pre-treated with interferon-gamma].
Onishi T; Machida T; Masuda F; Igarashi H
Hinyokika Kiyo; 1991 Jul; 37(7):671-8. PubMed ID: 1927765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
